US20010041739A1 - Use of PDE-4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection - Google Patents

Use of PDE-4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection Download PDF

Info

Publication number
US20010041739A1
US20010041739A1 US09/779,401 US77940101A US2001041739A1 US 20010041739 A1 US20010041739 A1 US 20010041739A1 US 77940101 A US77940101 A US 77940101A US 2001041739 A1 US2001041739 A1 US 2001041739A1
Authority
US
United States
Prior art keywords
infection
course
pde
mice
during
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/779,401
Other versions
US6436971B2 (en
Inventor
Peter DeMarsh
Susan Dillon
Gary Woodnutt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/779,401 priority Critical patent/US6436971B2/en
Assigned to SMITHKLINE BEECHAM CORPORATION reassignment SMITHKLINE BEECHAM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOODNUT, GARY, DEMARSH, PETER L., DILLON, SUSAN BETH
Publication of US20010041739A1 publication Critical patent/US20010041739A1/en
Application granted granted Critical
Publication of US6436971B2 publication Critical patent/US6436971B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • This invention relates to a method for the prophylaxis of or reducing the severity of post respiratory viral infection in the respiratory tract by bacteria by administering a PDE 4-specific inhibitor prior to or during the course of a viral infection or thereafter during the course of the bacterial infection.
  • Streptococcus pneumoniae is regarded as one of the most common causes of community-acquired pneumonia and is an important cause of illness and death in industrialized countries.
  • S. pneumoniae colonizes the human nasophararynx and in some circumstances the organisms spread to cause upper or lower respiratory tract infection.
  • the mechanisms underlying the transition from a benign colonization to disease are not well understood. A number of mechanisms have been proposed but the nature of this transition remains to be discovered.
  • pneumoniae phenotypes has been shown to be linked to the cell wall and the production of the capsular glycoprotein CbpA [Berube L. R., et al, 1999, Micro. Path. 26; 65-75 and Geelen S. et al, 1993, Infect. Immun., 61; 1538-1543].
  • This invention relates to a means for reducing the severity of or preventing a bacterial infection of the respiratiory tract following a respiratory viral tract infection by administering an effective amount of a PDE 4-specific inhibitor alone or in combination with a pharmaceutically acceptable excipient prior to or during the course of the viral infection, during the course of both the viral infection and the bacterial infection following thereafter, or during the course of the bacterial infection alone.
  • FIG. 1 is a graph of the S. pneumoniae LD 50 determination in non-infected vs. sub-lethally influenza infected mice.
  • FIG. 2 is a chart of the survival following S. pneumoniae challenge following treatment with a PDE 4 inhibitor.
  • FIG. 3 is a chart of the colony-forming-units/mouse following a S. pneumoniae challenge following treatment with a PDE 4 inhibitor.
  • This invention can be used in those situations where a respiratory viral infection is or will most likely occur. It can be used regardless of the type of viral material causing the respiratory infection and regardless of the locus of the infection, be it in the upper respiratory tract or the lower tract or both. Numerous viruses are known to be involved in respiratory viral infections, including but not limited to Rhinovirus, Influenza, Respiratory Syncytial Virus, Parainfluenza, Adenovirus, Enterovirus and Coronavirus.
  • the PDE4 inhibitor is administered in several ways: i) during the course of the respiratory viral infection, starting at any time and running for less that the full length of the viral infection; ii) during the whole of the course of the respiratory viral infection or some part thereof, and during the whole of the course of the bacterial infection, or some part thereof; or iii) at the start of or during the course of the bacterial infection or some part thereof.
  • the inhibitor can be administered prior to the onset of a respiratory viral infection, and preferably continued for some period during the course of the infection.
  • an inhibitor can be administered intermitently during the respiratory viral infection phase, or over the course of both the viral infection and the subsequent bacterial infection.
  • the inhibitors of interest in this invention are PDE 4 inhibitors. Of particular interest are those which are specific for PDE 4.
  • a preferred group of inhibitors are those that have an IC 50 ratio (high/low binding) of about 0.1 or greater as further described in U.S. Pat. No. 5,998,428; this patent is incorporated herein in full by reference as if fully set forth herein.
  • a preferred standard for PDE 4-specific inhibitors which can be used in this invention is one where the compound has an IC 50 ratio of about 0.1 or greater; said ratio being the ratio of the IC 50 value for competing with the binding of 1 nM of [ 3 H]R-rolipram to a form of PDE 4 which binds rolipram with a high affinity over the IC 50 value for inhibiting the PDE 4 catalytic activity of a form which binds rolipram with a low affinity using 1 ⁇ M[ 3 H]-cAMP as the substrate.
  • PDE 4 inhibitors that may be included in these formulations include those set out in U.S. Pat. No. 5,552,438 issued Sep. 3, 1996. This patent and the compounds it discloses are incorporated herein in full by reference.
  • the compound of particular interest, which is disclosed in U.S. Pat. No. 5,552,438, is cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid (Ariflo®) and its salts, esters, pro-drugs or physical forms.
  • Other PDE 4 inhibitors which may be of interest include: AWD-12-281 from Astra (Hofgen, N. et al.
  • Preferred compounds of this invention are those which have an IC 50 ratio of greater than 0.5, and particularly those compounds having a ratio of greater than 1.0.
  • the most preferred compounds are roflumilast and cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid.
  • PDE 4 inhibitors can be combined with other methods for treating influenza and/or bacterial infections.
  • a PDE 4 inhibitor could be co-administered with a treatment for influenza during the course of the viral infection.
  • examples of such drugs are alpha and beta interferon, Inosine pranobex, moroxydine hydrochloride, zanamivir, rimantadine, rimantadine hydrochloride, oseltamivir phosphate and the like.
  • an anti-infective agent may be co-administered at the same time or in conjunction with the PDE 4 inhibitor.
  • antibiotics they are a very diverse class of compounds which often classified and discussed in groups. Herein those of greatest interest will be the drugs and preparations which treat infections in the lung.
  • S. pneumoniae is often found in patients with pneumonia. It is sensitive to the penicillins, benzylpenicillin, amoxycillin, or ampicillin; to cephalosporins; to erythromycin; or to co-trimoxazole.
  • Mycoplasma pneumoniae is also an important cause of community-acquired pneumonia. Erythromycin or tetracycline are the antibacterials of choice against M. pneumoniae; erythromycin is usually recommended when mycoplasmal pneumonia is suspected.
  • Bacteria that may be responsible for community-acquired pneumonia include Haemophilus influenzae and, more recently, Moraxella (Branhamella) catarrhalis especially in patients with chronic lung disease; Legionella pneumophila (see Legionnaires' Disease); Chlamydia psittaci (see Psittacosis); Chlamydia pneumoniae (formerly known as the TWAR strain of Chlamydia psittaci ); and Coxiella burnetii (see Q fever).
  • a fuller discussion of pulmonary infections and antibiotics for their treatment can be found in the likes of Tomes CPSTM System from Micromedex. This publication is available on the Web courtesy of Micromedex, Inc., The section relating to antibiotics relevant to this invention has the URL
  • the PDE 4 inhibitorin is preferred to administer an amount between about 1 mg to 200 mg, more preferably 5 to 100 mg, and most preferably between 5, or 10 to 60 mg of the active ingredient. Additional preferred dosage amounts are about within these ranges are 10, 15, 20, 30, 40, 50, 60, 70, 80 or 90 mg per preparation.
  • the inhibitor can be administered by any route.
  • a perferred formulation will be an oral immediate release tablet or a oral controlled release tablet.
  • the inhibitor may be administered up to 6 times per day, though a twice or once a day dosing regime is preferred.
  • the assay used here-in is a murine model where the subject is administered a sub-lethal influenza infection followed by Streptococcus pneumoniae co-infection and then evaluated for survival.
  • mice are infected with a dose of influenza virus that leads to a non-lethal self-limiting infection.
  • Mice that had recently cleared an influenza infection required 4 loglo fewer S. pneumoniae to cause mortality than normal non-influenza challenged animals.
  • mice dosed with saline required 10 4 cfu of S. pneumoniae to show significant mortality
  • influenza challenged animals showed significant mortality with as few as 280-cfu pneumococcl.
  • mice Male CBA/J mice obtained from Jackson Laboratories (Bar Harbor, Me.) 3 to 4 weeks of age were utilized. Mice were housed 10 per cage in standard laboratory plastic caging and fed lab chow and water ab libitum. All animal procedures were performed in accordance with the highest standards for the humane handling, care and treatment of research animals.
  • Bacteria Two separate S. pneumoniae clinical isolates (strains #1629 and #0100993) were individually animal-passaged in mice and subsequently recovered and plated onto sheep red blood cell trypticase soy agar (TSA) then stored frozen at ⁇ 70° C. The re-isolated organisms were grown overnight on chocolate TSA (Becton Dickinson, Md.) and harvested in saline. The concentration of the stock was determined by absorbance (560 nm) using a spectrophotometer (Beckman DU 640B, Calif.). Inoculum doses were based on viable counts determined by scoring colony-forming units on sheep reb blood TSA.
  • Virus Influenza type A virus strain A/PR/8/34 sub type H1N1 (American Type Culture Collection, Rockville, Md.) was propagated in the allantoic cavity of 10 day old fertilized chicken eggs. The eggs were incubated for 48 hrs at 37° C., refrigerated for 2 1 ⁇ 2 hours at 4° C. then the allantonic fluid was harvested. Pooled allantoic fluid was centrifuged (1,000 rcf; 15 min; 4° C.) to remove cells, and then divided into aliquots for storage at ⁇ 70° C. The titer of the stock culture of virus was 1.0 ⁇ 10 9 TCID 50 /ml.
  • mice were anesthetized with ketamine/xylazine (40 mg/kg;10 mg/kg) and inoculated intranasally (IN) with 50 ⁇ l of influenza virus or vehicle control. Mice that were co-infected with bacteria were anesthetized as above then infected IN with 25 ⁇ l of bacterial suspension.
  • Virus Titrations Lungs were removed aseptically and placed in vials containing 1 micron glass beads (Biospec Products, Bartlesville, Okla.) and 1 ml. of Eagles minimal essential medium with penicillin and streptomycin. The lungs were homogenized for 45 seconds using a mini-bead beater (Biospec Products, Bartlesville, Okla.); the vials were then centrifuged at 1,000 rcf for 15 minutes at 4° C., and the lung supernatants were frozen at ⁇ 20° C. Virus was quantitated in an in vitro microassay using Madin-Darby canine kidney (MDCK) cells (r).
  • MDCK Madin-Darby canine kidney
  • cytokine concentrations and thresholds were determined as described by the manufacturer; TNF- ⁇ , IL-6, IFN- ⁇ , and KC (R&D Systems, Minneapolis, Minn.) IL-10, IL-1 ⁇ (Biosource International, Camarillo, Calif.).
  • Penh value is a function of the proportion of maximal expiratory to maximal inspiratory box pressure signals and the timing of expiration.
  • mice challenged intranasally (IN) with as few as 350 TCID 50 of influenza strain A/PR/8134 resulted in 80% to 90% of the mice succumbing to the infection.
  • Lower doses of virus resulted in over 95% of the animals surviving.
  • a dose range of 10 to 50 TCID 50 was selected as a sub-lethal dose for use in co-infection models.
  • Acute Influenza A infection results in a reduction in pulmonary functions.
  • Whole body plethysmography is currently accepted as a measurement for pulmonary resistance in allergic or infected mice (Haczku et al. 1997; Hamelmann et al. 1997a; Hamelmann et al. 1997b; Schwarze et al. 1998; van Schaik et al. 1998).
  • Penh was used in this study as a parameter representing pulmonary functions.
  • Uninfected or Influenza A/PR/8/34 infected mice were evaluated daily for 16 days. Penh values were elevated above baseline (0.4-0.5) in all animals between days 5-16 post infection.
  • the wet lungs weights indicated an increasing pneumonitis with significant increases in wet weight as early as day 2 after infection followed by a rapid increase over days 5 and 6.
  • the dry lung weights did not reach statistically significant increases in weight until day 6 after infection. Otherwise the dry lung wts reflected the wet lung weights.
  • the wet lung weights showed small but statistically significant increases as early as day 2 with larger increases on days 5 to 6.
  • the dry lung weights did not show significant increases until day 6 after infection. Both the wet and dry weights remained elevated after the virus cleared, day 9.
  • cytokine response to influenza challenge was evaluated in bronchiolar lavage fluid (BALF), increases were seen in IL-6, IFN ⁇ , and the chemokine KC (Table 1). All showed peak levels on day 8 after challenge with levels decreasing to pre-infection levels by day 10. TNF ⁇ , IL-10, IL-1 ⁇ , and IL-2 were also evaluated, however no significant elevation in levels ware found for these cytokines at any time point. TABLE 1 Table I.
  • Cytokine Concentration in the BALF from Sub-lethally Infected Mice Day 1 Day 3 Day 6 Day 8 Day 10 Day 13 Day 15 IL-6 120 ⁇ 15 118 ⁇ 12 448 ⁇ 221 575 ⁇ 170* 279 ⁇ 194 116 ⁇ 6 128 ⁇ 10 IFN- ⁇ 34 ⁇ 10 33 ⁇ 16 692 ⁇ 328* 2392 ⁇ 783* 87 ⁇ 49 30 ⁇ 5 30 ⁇ 2 KC 16 ⁇ 2 24 ⁇ 7 112 ⁇ 38* 206 ⁇ 52* 73 ⁇ 42 42 ⁇ 11 23 ⁇ 13 TNF- ⁇ 40 ⁇ 21 16 ⁇ 10 19 ⁇ 2 33 ⁇ 15 16 ⁇ 5 13 ⁇ 1 22 ⁇ 13 IL-10 272 ⁇ 59 177 ⁇ 96 255 ⁇ 86 242 ⁇ 117 148 ⁇ 35 107 ⁇ 49 208 ⁇ 112 IL-1 ⁇ 84 ⁇ 29 203 ⁇ 90 130 ⁇ 19 128 ⁇
  • mice were infected IN with a sub-lethal dose of influenza virus or non-virally infected vehicle controls.
  • S. pneumoniae strain #0100993
  • the non-virally infected mice were resistant to infection requiring 2.8 ⁇ 10 7 cfu/mouse S. pneumoniae to lead to no animals surviving.
  • the calculated LD 50 for non-virally infected mice challenged with S. pneumoniae was 4.7 ⁇ 10 5 cfu/mouse.
  • the mice challenged with a sub-lethal dose of influenza were sensitive to a second challenge with S. pneumoniae with all the mice co-infected with 2.8 ⁇ 10 2 cfu/mouse of S.
  • the LD 50 for the virus infected mice was only 66 cfu/mouse. These results replicated with a second strain of S. pneumoniae (strain # 1629), the non-virus infected animals showed a S. pneumoniae LD 50 of 2.4 ⁇ 10 5 cfu/mouse while the virus challenged animals showed an LD 50 of only 47 cfu/mouse.
  • mice were challenged with influenza as above and then separate groups were challenged with 375 cfu of S. pneumoniae on day 7 through 15 (FIG. 1). Mice were challenged with a sub-lethal dose of influenza virus; n 10 per group. On days 7 to 15 after infection individual groups of mice were challenged with 375 cfu/mouse of S. pneumoniae. The mice challenged with pneumococci just before of just after the virus is cleared, days 7 to 9, showed high susceptibility to the secondary infection.
  • mice were infected with virus as above and challenged on day 9 with S. pneumoniae (strain # 0100993) 492 cfu/mouse. Mice were sacrificed at 2, 24 and 48 hrs post bacterial challenge and whole lungs were homogenized and the number of S. pneumoniae determined for each animal. Two hrs after infection there were few recoverable organisms from the lungs of the mice. However, by 24 hrs post infection the number of recovered S. pneumoniae were 8.9 ⁇ 10 5 cfu/mouse, at 48 hrs the numbers had climbed to 2.1 ⁇ 10 6 cfu/mouse.
  • mice were treated orally with 10 or 30 mg/kg of cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid once daily on days 0 to 9.
  • the vehicle was 2% methylcellulose.
  • mice treated with control diluent had an LD 50 of 72 and Ariflo (10, 30 mg/kg) treated mice had a LD 50 of 252 and 221 cfu/mouse respectively of S. pneumoniae. See FIG. 3 for survival rates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a method for the prophylaxis of or reducing the severity of post-viral bacterial infection by administering a PDE 4-specific inhibitor prior to or during the course of a viral infection or thereafter during the course of the bacterial infection.

Description

    AREA OF THE INVENTION
  • This invention relates to a method for the prophylaxis of or reducing the severity of post respiratory viral infection in the respiratory tract by bacteria by administering a PDE 4-specific inhibitor prior to or during the course of a viral infection or thereafter during the course of the bacterial infection. [0001]
    • BACKGROUND
  • Primary respiratory tract viral infections have been shown to lead to increased susceptibility to secondary bacterial infections [Loosli C. G. 1973, [0002] Med. 52, 369-384; Stuart-Harris C. H., Laird J., Tyrell D. A., Kelsall M. H., Franks Z. C., Pownall M. 1949, J. Hyg. 47; 434; and Stuart-Harris C. H. 1966, Brit. Med. J. 149; 217]. The mechanisms of this susceptibility are poorly understood. And there is no prophylactics or treatments available for reducing or moderating this susceptibility. Herein there is provided a model for studying this phenomenon and a demonstrated method for reducing this susceptibility by administering a PDE 4 specific inhibitor.
  • [0003] Streptococcus pneumoniae is regarded as one of the most common causes of community-acquired pneumonia and is an important cause of illness and death in industrialized countries. S. pneumoniae colonizes the human nasophararynx and in some circumstances the organisms spread to cause upper or lower respiratory tract infection. The mechanisms underlying the transition from a benign colonization to disease are not well understood. A number of mechanisms have been proposed but the nature of this transition remains to be discovered.
  • Epidemiological studies have demonstrated that viral infections pre-dispose the host lung to bacterial pneumonia and secondary bacterial pneumonia is the most frequent complication of influenza infection in man [Loosli C. G. 1973, [0004] Med. 52, 369-384; Stuart-Harris C. H., Laird J., Tyrell D. A., Kelsall M. H., Franks Z. C., Pownall M. 1949, J. Hyg. 47; 434; and Stuart-Harris C. H. 1966, Brit. Med. J. 149; 217]. Investigators have demonstrated in vitro that cells stimulated with either cytokines or virus show enhanced bacterial adherence and that bacterial adherence to host tissues is an essential step in bacterial colonization and infections [Jones W. T., Menna J. H. 1982, Infect. Immun. 38; 791-794; Jiang Z., Nagata N., Molina E., Bakaletz L. O., Hawkins H., Patel J. A. 1999, Infect. Immun. 67; 187-192; Sanford B. A., Shelokov A., Ramsay M. A. 1978, J. Infect. Dis. 137; 176-181; Geelen S., Bhattacharyya C., Tuomanen E. 1993, Infect. Immun. 61; 1538-1543; and Hakansson A., Kidd A., Wadell G., Sabharwal H., Svanborg C. 1994, Infect. Immun. 62, 2707-2714.]
  • Phase variation of pneumococci has been demonstrated to be one of the virulence mechanisms of respiratory tract infections. For [0005] S. pneumoniae the transparent phenotype has been shown to adhere to lung epithelial cells and to be more virulent in an infant rat colonization model than the opaque phenotype [Kim J. O., Weiser J. N. 1998, J. Infect. Dis. 177:368-377; and Weiser J. N., Austrian R., Sreenivasan P. K., Masure H. R. 1994, Infect. Immun. 62; 2582-2589]. The mechanism of the altered virulence of S. pneumoniae phenotypes has been shown to be linked to the cell wall and the production of the capsular glycoprotein CbpA [Berube L. R., et al, 1999, Micro. Path. 26; 65-75 and Geelen S. et al, 1993, Infect. Immun., 61; 1538-1543].
  • Here-in there is described a murine model of sub-lethal influenza infection followed by [0006] Streptococcus pneumoniae co-infection. Also disclosed is the finding that administrating a PDE 4-specific inhibitor reduces the susceptibility of a mammal to post-viral bacterial infection.
    • SUMMARY OF THE INVENTION
  • This invention relates to a means for reducing the severity of or preventing a bacterial infection of the respiratiory tract following a respiratory viral tract infection by administering an effective amount of a PDE 4-specific inhibitor alone or in combination with a pharmaceutically acceptable excipient prior to or during the course of the viral infection, during the course of both the viral infection and the bacterial infection following thereafter, or during the course of the bacterial infection alone.[0007]
    • DESCRIPTION OF THE FIGURES
  • FIG. 1 is a graph of the [0008] S. pneumoniae LD50 determination in non-infected vs. sub-lethally influenza infected mice.
  • FIG. 2 is a chart of the survival following [0009] S. pneumoniae challenge following treatment with a PDE 4 inhibitor.
  • FIG. 3 is a chart of the colony-forming-units/mouse following a [0010] S. pneumoniae challenge following treatment with a PDE 4 inhibitor.
    • SPECIFIC EMBODIMENTS
  • Respiratory viral infections and course of treatment [0011]
  • This invention can be used in those situations where a respiratory viral infection is or will most likely occur. It can be used regardless of the type of viral material causing the respiratory infection and regardless of the locus of the infection, be it in the upper respiratory tract or the lower tract or both. Numerous viruses are known to be involved in respiratory viral infections, including but not limited to Rhinovirus, Influenza, Respiratory Syncytial Virus, Parainfluenza, Adenovirus, Enterovirus and Coronavirus. [0012]
  • The PDE4 inhibitor is administered in several ways: i) during the course of the respiratory viral infection, starting at any time and running for less that the full length of the viral infection; ii) during the whole of the course of the respiratory viral infection or some part thereof, and during the whole of the course of the bacterial infection, or some part thereof; or iii) at the start of or during the course of the bacterial infection or some part thereof. In addition, the inhibitor can be administered prior to the onset of a respiratory viral infection, and preferably continued for some period during the course of the infection. Furthermore, an inhibitor can be administered intermitently during the respiratory viral infection phase, or over the course of both the viral infection and the subsequent bacterial infection. [0013]
  • PDE 4 Inhibitors [0014]
  • The inhibitors of interest in this invention are PDE 4 inhibitors. Of particular interest are those which are specific for PDE 4. A preferred group of inhibitors are those that have an IC[0015] 50 ratio (high/low binding) of about 0.1 or greater as further described in U.S. Pat. No. 5,998,428; this patent is incorporated herein in full by reference as if fully set forth herein. A preferred standard for PDE 4-specific inhibitors which can be used in this invention is one where the compound has an IC50 ratio of about 0.1 or greater; said ratio being the ratio of the IC50 value for competing with the binding of 1 nM of [3H]R-rolipram to a form of PDE 4 which binds rolipram with a high affinity over the IC50 value for inhibiting the PDE 4 catalytic activity of a form which binds rolipram with a low affinity using 1 μM[3H]-cAMP as the substrate.
  • Other PDE 4 inhibitors that may be included in these formulations include those set out in U.S. Pat. No. 5,552,438 issued Sep. 3, 1996. This patent and the compounds it discloses are incorporated herein in full by reference. The compound of particular interest, which is disclosed in U.S. Pat. No. 5,552,438, is cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid (Ariflo®) and its salts, esters, pro-drugs or physical forms. Other PDE 4 inhibitors which may be of interest include: AWD-12-281 from Astra (Hofgen, N. et al. 15th EFMC Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, Abst P.98); a 9-benzyladenine derivative nominated NCS-613 (INSERM); D-4418 from Chiroscience and Schering-Plough; a benzodiazepine PDE 4 inhibitor identified as CI-1018 (PD-168787; Parke-Davis/Warner-Lambert); a benzodioxole derivative Kyowa Hakko disclosed in WO 9916766; V-1 1294A from Napp (Landells, L. J. et al. Eur Resp J [Annu Cong Eur Resp Soc (Sept 19-23, Geneva) 1998] 1998, 12(Suppl. 28): Abst P2393); roflumilast (CAS reference No 162401-32-3) and a pthalazinone (WO 9947505) from Byk-Gulden; and a compound identified as T-440 (Tanabe Seiyaku; Fujii, K. et al. [0016] J Pharmacol Exp Ther, 1998, 284(1): 162). Preferred compounds of this invention are those which have an IC50 ratio of greater than 0.5, and particularly those compounds having a ratio of greater than 1.0. The most preferred compounds are roflumilast and cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid.
  • In addition, one or more of these PDE 4 inhibitors can be combined with other methods for treating influenza and/or bacterial infections. For example, a PDE 4 inhibitor could be co-administered with a treatment for influenza during the course of the viral infection. Examples of such drugs are alpha and beta interferon, Inosine pranobex, moroxydine hydrochloride, zanamivir, rimantadine, rimantadine hydrochloride, oseltamivir phosphate and the like. [0017]
  • If the PDE 4 inhibitor is administered during the course of the bacterial infection, an anti-infective agent may be co-administered at the same time or in conjunction with the PDE 4 inhibitor. [0018]
  • As regards antibiotics, they are a very diverse class of compounds which often classified and discussed in groups. Herein those of greatest interest will be the drugs and preparations which treat infections in the lung. [0019] S. pneumoniae is often found in patients with pneumonia. It is sensitive to the penicillins, benzylpenicillin, amoxycillin, or ampicillin; to cephalosporins; to erythromycin; or to co-trimoxazole. Mycoplasma pneumoniae is also an important cause of community-acquired pneumonia. Erythromycin or tetracycline are the antibacterials of choice against M. pneumoniae; erythromycin is usually recommended when mycoplasmal pneumonia is suspected. Bacteria that may be responsible for community-acquired pneumonia include Haemophilus influenzae and, more recently, Moraxella (Branhamella) catarrhalis especially in patients with chronic lung disease; Legionella pneumophila (see Legionnaires' Disease); Chlamydia psittaci (see Psittacosis); Chlamydia pneumoniae (formerly known as the TWAR strain of Chlamydia psittaci); and Coxiella burnetii (see Q fever). A fuller discussion of pulmonary infections and antibiotics for their treatment can be found in the likes of Tomes CPS™ System from Micromedex. This publication is available on the Web courtesy of Micromedex, Inc., The section relating to antibiotics relevant to this invention has the URL
  • http://www.tomescps.com/DKS/DATAJMT/MTM1-z.htm#l -a5-328-k. [0020]
  • For the purposes of this invention, it is preferred to administer the PDE 4 inhibitorin an amount between about 1 mg to 200 mg, more preferably 5 to 100 mg, and most preferably between 5, or 10 to 60 mg of the active ingredient. Additional preferred dosage amounts are about within these ranges are 10, 15, 20, 30, 40, 50, 60, 70, 80 or 90 mg per preparation. The inhibitor can be administered by any route. A perferred formulation will be an oral immediate release tablet or a oral controlled release tablet. The inhibitor may be administered up to 6 times per day, though a twice or once a day dosing regime is preferred. [0021]
  • Assay [0022]
  • The assay used here-in is a murine model where the subject is administered a sub-lethal influenza infection followed by [0023] Streptococcus pneumoniae co-infection and then evaluated for survival. In this model, mice are infected with a dose of influenza virus that leads to a non-lethal self-limiting infection. Mice that had recently cleared an influenza infection required 4 loglo fewer S. pneumoniae to cause mortality than normal non-influenza challenged animals. While mice dosed with saline required 104 cfu of S. pneumoniae to show significant mortality, influenza challenged animals showed significant mortality with as few as 280-cfu pneumococcl.
  • Mice: Male CBA/J mice obtained from Jackson Laboratories (Bar Harbor, Me.) 3 to 4 weeks of age were utilized. Mice were housed 10 per cage in standard laboratory plastic caging and fed lab chow and water ab libitum. All animal procedures were performed in accordance with the highest standards for the humane handling, care and treatment of research animals. [0024]
  • Preparation 1 [0025]
  • Bacteria: Two separate [0026] S. pneumoniae clinical isolates (strains #1629 and #0100993) were individually animal-passaged in mice and subsequently recovered and plated onto sheep red blood cell trypticase soy agar (TSA) then stored frozen at −70° C. The re-isolated organisms were grown overnight on chocolate TSA (Becton Dickinson, Md.) and harvested in saline. The concentration of the stock was determined by absorbance (560 nm) using a spectrophotometer (Beckman DU 640B, Calif.). Inoculum doses were based on viable counts determined by scoring colony-forming units on sheep reb blood TSA.
  • [0027] Preparation 2
  • Virus: Influenza type A virus strain A/PR/8/34 sub type H1N1 (American Type Culture Collection, Rockville, Md.) was propagated in the allantoic cavity of 10 day old fertilized chicken eggs. The eggs were incubated for 48 hrs at 37° C., refrigerated for 2 ½ hours at 4° C. then the allantonic fluid was harvested. Pooled allantoic fluid was centrifuged (1,000 rcf; 15 min; 4° C.) to remove cells, and then divided into aliquots for storage at −70° C. The titer of the stock culture of virus was 1.0×10[0028] 9 TCID50/ml.
  • Preparation 3 [0029]
  • Mice were anesthetized with ketamine/xylazine (40 mg/kg;10 mg/kg) and inoculated intranasally (IN) with 50 μl of influenza virus or vehicle control. Mice that were co-infected with bacteria were anesthetized as above then infected IN with 25 μl of bacterial suspension. [0030]
  • Preparation 4 [0031]
  • Virus Titrations: Lungs were removed aseptically and placed in vials containing 1 micron glass beads (Biospec Products, Bartlesville, Okla.) and 1 ml. of Eagles minimal essential medium with penicillin and streptomycin. The lungs were homogenized for 45 seconds using a mini-bead beater (Biospec Products, Bartlesville, Okla.); the vials were then centrifuged at 1,000 rcf for 15 minutes at 4° C., and the lung supernatants were frozen at −20° C. Virus was quantitated in an in vitro microassay using Madin-Darby canine kidney (MDCK) cells (r). Serial dilutions of lung homogenates (in medium plus 2.5 ug/ml trypsin) were added to round-bottom microtiter wells containing adherent MDCK cells. After 5 days of incubation at 37° C. (5% CO[0032] 2), 50 μl of 0.5% chick red blood cells were added per well, and agglutination was read after 1 hour at room temperature. The virus titer is expressed as 50% tissue culture infective dose (TCID50) calculated by logistic regression (s).
  • Preparation 5 [0033]
  • Bacterial Titrations: Lungs were harvested as above and homogenized ([0034] Stomacher 80 Seward Medical, London, England) in 1.0 ml of saline. Serial dilutions were made in saline and inoculated onto sheep red blood cell TSA for enumeration.
  • Preparation 6 [0035]
  • Histochemistry: Whole lungs were inflated-fixed with 10% formalin in phosphate-buffered saline and immersed in fixative for 24 hrs at 4° C. Tissues were processed for paraffin sectioning using an automated tissue processor. Paraffin-embedded lungs were serially sectioned at 6 μm and prepared for hemotoxylin and eosin (H&E) staining. [0036]
  • Preparation 7 [0037]
  • Cytokine analysis: Bronchiolar alveolar lavage fluid (BALF) cytokine levels were measured by quantitative ELISA using commercially available kits. Mice were sacrificed and the trachea exposed, a cannula was inserted and ligated. By syringe each lung was flushed three times with 1 ml of normal saline. The BALF was centrifuged at 2000 rcf for 1 min. and the supernatant was stored at −70° C. The cytokine concentrations and thresholds were determined as described by the manufacturer; TNF-α, IL-6, IFN-γ, and KC (R&D Systems, Minneapolis, Minn.) IL-10, IL-1β (Biosource International, Camarillo, Calif.). [0038]
  • [0039] Preparation 8
  • Determination of pulmonary functions: Barometric plethysmography was conducted on unrestrained mice using whole body plethysmography (Buxco, Troy, N.Y.), as described (Hamelmann et al, 1997, Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography, Amer. J. of Resp. Crit. Care Med. 156, 766-775.). Briefly, individual chambers were calibrated prior to each reading, mice were placed in the main chamber, and pressure differences between the main chamber and a reference chamber were recorded for 2 minutes. Using the Biosystem Pulmonary Analyzer software (Buxco) the resultant box pressure was used to calculate the phases of the respiratory cycle, tidal volumes, and enhanced pause (Penh). Penh value is a function of the proportion of maximal expiratory to maximal inspiratory box pressure signals and the timing of expiration. Uninfected or Influenza A/PR/8/34 infected mice dosed with Ariflo® at 10 or 30 mg/Kg/day (days 0-8) were evaluated daily for 16 days. [0040]
    • EXAMPLE 1
  • Sub-lethal Influenza Infection Model. [0041]
  • Initial 21-day survival studies determined that mice challenged intranasally (IN) with as few as 350 TCID[0042] 50 of influenza strain A/PR/8134 resulted in 80% to 90% of the mice succumbing to the infection. Lower doses of virus resulted in over 95% of the animals surviving. From these studies a dose range of 10 to 50 TCID50 was selected as a sub-lethal dose for use in co-infection models. To confirm that mice challenged with this low inocula have a self-limiting infection, mice were challenged IN with 10 to 50 TCID50 and sacrificed 2 hrs after infection, on days 1 to 11 and day 14. The lungs were harvested and the viral titers determined. Two hours after infection there was no virus detectable from the lungs of the mice. However, by day 1 after infection there was detectable virus in the lung homogenates. The virus titers peaked on day 5 with 4.8×105 TCID50 in the lungs. The virus titers decreased after day 5 with all the animals being clear of virus by day 9 after infection.
  • Histopathology from these animals show a progressive lower respiratory tract infection with heavy thickening of the alveoli by day 6 after infection. There is interstitial pneumonitis with capillary thrombosis and necrosis of the of the alveolar walls. Both alveolar type I and II cells lining the alveolar spaces slough. While the virus was reduced to undetectable levels by day 9 after infection, considerable consolidation of the lungs remains. By [0043] day 15 after infection, although some consolidated areas remain, there are increased areas of improved lung.
  • Acute Influenza A infection results in a reduction in pulmonary functions. Whole body plethysmography is currently accepted as a measurement for pulmonary resistance in allergic or infected mice (Haczku et al. 1997; Hamelmann et al. 1997a; Hamelmann et al. 1997b; Schwarze et al. 1998; van Schaik et al. 1998). Penh was used in this study as a parameter representing pulmonary functions. Uninfected or Influenza A/PR/8/34 infected mice were evaluated daily for 16 days. Penh values were elevated above baseline (0.4-0.5) in all animals between days 5-16 post infection. [0044]
  • The wet and dry lung weights from sub-lethal influenza challenged mice were evaluated as follows: The wet and dry lung wts were evaluated from mice sub-lethally challenged with influenza virus; n=4 per group. The wet lungs weights, indicated an increasing pneumonitis with significant increases in wet weight as early as [0045] day 2 after infection followed by a rapid increase over days 5 and 6. The dry lung weights did not reach statistically significant increases in weight until day 6 after infection. Otherwise the dry lung wts reflected the wet lung weights. The wet lung weights showed small but statistically significant increases as early as day 2 with larger increases on days 5 to 6. The dry lung weights did not show significant increases until day 6 after infection. Both the wet and dry weights remained elevated after the virus cleared, day 9.
  • The cytokine response to influenza challenge was evaluated in bronchiolar lavage fluid (BALF), increases were seen in IL-6, IFNγ, and the chemokine KC (Table 1). All showed peak levels on [0046] day 8 after challenge with levels decreasing to pre-infection levels by day 10. TNFα, IL-10, IL-1β, and IL-2 were also evaluated, however no significant elevation in levels ware found for these cytokines at any time point.
    TABLE 1
    Table I. Cytokine Concentration (pg/ml) in the BALF from Sub-lethally Infected Mice
    Day 1 Day 3 Day 6 Day 8 Day 10 Day 13 Day 15
    IL-6 120 ± 15 118 ± 12 448 ± 221  575 ± 170* 279 ± 194 116 ± 6 128 ± 10
    IFN-γ  34 ± 10  33 ± 16 692 ± 328* 2392 ± 783*  87 ± 49  30 ± 5  30 ± 2
    KC  16 ± 2  24 ± 7 112 ± 38*  206 ± 52*  73 ± 42  42 ± 11  23 ± 13
    TNF-α  40 ± 21  16 ± 10  19 ± 2  33 ± 15  16 ± 5  13 ± 1  22 ± 13
    IL-10 272 ± 59 177 ± 96 255 ± 86  242 ± 117 148 ± 35 107 ± 49 208 ± 112
    IL-1β  84 ± 29 203 ± 90 130 ± 19  128 ± 89  99 ± 79  61 ± 58 105 ± 41
    IL-2  2 ± 1  2 ± 1  2 ± 1   2 ± 1  2 ± 1  2 ± 1  1 ± 1
    • EXAMPLE 2
  • Establishment of Bacterial Co-Infection Model [0047]
  • In initial studies mice were infected IN with a sub-lethal dose of influenza virus or non-virally infected vehicle controls. On day 9 after infection the mice were given a second challenge IN with [0048] S. pneumoniae (strain #0100993). The non-virally infected mice were resistant to infection requiring 2.8×107 cfu/mouse S. pneumoniae to lead to no animals surviving. The calculated LD50 for non-virally infected mice challenged with S. pneumoniae was 4.7×105 cfu/mouse. In contrast, the mice challenged with a sub-lethal dose of influenza were sensitive to a second challenge with S. pneumoniae with all the mice co-infected with 2.8×102 cfu/mouse of S. pneumoniae dying. The LD50 for the virus infected mice was only 66 cfu/mouse. These results replicated with a second strain of S. pneumoniae (strain # 1629), the non-virus infected animals showed a S. pneumoniae LD50 of 2.4×105 cfu/mouse while the virus challenged animals showed an LD50 of only 47 cfu/mouse.
  • Initial studies in the bacterial co-infection model were performed on day 9 after virus challenge because that was the first day the animals were influenza virus culture negative. A study was done to determine the length of time that the increased sensitivity to infection with [0049] S. pneumoniae was sustained. In this study mice were challenged with influenza as above and then separate groups were challenged with 375 cfu of S. pneumoniae on day 7 through 15 (FIG. 1). Mice were challenged with a sub-lethal dose of influenza virus; n=10 per group. On days 7 to 15 after infection individual groups of mice were challenged with 375 cfu/mouse of S. pneumoniae. The mice challenged with pneumococci just before of just after the virus is cleared, days 7 to 9, showed high susceptibility to the secondary infection. The mice challenged with pneumococci at latter time points, day 10 to 15, showed increasing resistance to infection. The animals did not return to normal levels of pneumococcal resistance at any time point tested up to 15 days. The mice co-infected with bacteria on days 7 to 9 all had a low survival rate. Mice co-infected on later days showed improved survival, although this improvement did not make the virus challenged animals as resistant to infection as normal saline challenged animals.
  • To determine if the decrease in survival demonstrated in co-infected mice was due to bacterial pneumonia, mice were infected with virus as above and challenged on day 9 with [0050] S. pneumoniae (strain # 0100993) 492 cfu/mouse. Mice were sacrificed at 2, 24 and 48 hrs post bacterial challenge and whole lungs were homogenized and the number of S. pneumoniae determined for each animal. Two hrs after infection there were few recoverable organisms from the lungs of the mice. However, by 24 hrs post infection the number of recovered S. pneumoniae were 8.9×105 cfu/mouse, at 48 hrs the numbers had climbed to 2.1×106 cfu/mouse. Later time points could not be taken since the animals start to succumb to the infection on day 3 after infection with all the animals dying by day 5. These results replicated with a second strain of S. pneumoniae (strain # 1629), with 3.8×105 cfu/mouse being recovered from the lungs at 24 hrs after infection climbing to 1.6×108 cfu/mouse at 48 hrs post bacterial challenge.
    • EXAMPLE 3
  • Pretreatment With a PDE 4 Inhibitor [0051]
  • In this study the mice were treated orally with 10 or 30 mg/kg of cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid once daily on [0052] days 0 to 9. The vehicle was 2% methylcellulose. These mice were infected with a sub-lethal dose of influenza virus IN as described above. On day 9 after influenza infection the mice were challenged IN with S. pneumoniae (strain #0100993) prepared as described above. The mice were then followed for survival. The mice treated with control diluent had an LD50 of 72 and Ariflo (10, 30 mg/kg) treated mice had a LD50 of 252 and 221 cfu/mouse respectively of S. pneumoniae. See FIG. 3 for survival rates.

Claims (10)

What is claimed is:
1. A method for reducing the severity of or preventing a bacterial infection of the respiratiory tract following a respiratory viral tract infection by administering an effective amount of a PDE 4-specific inhibitor alone or in combination with a pharmaceutically acceptable excipient prior to or during the course of the viral infection, during the course of both the viral infection and the bacterial infection following thereafter, or during the course of the bacterial infection alone.
2. The method of
claim 1
 wherein the PDE 4 inhibitor is administered during the course of the viral infection.
3. The method of
claim 1
 wherein the PDE 4 inhibitor is administered during the course of the viral infection and during the course of the bacterial infection.
4. The method of
claim 1
 wherein the PDE 4 inhibitor is administered during the course of the bacterial infection.
5. The method of
claim 3
 wherein an antibiotic is administered during the course of the bacterial infection.
6. The method of
claim 4
 wherein an antibiotic is administered during the course of the bacterial infection.
7. The method of
claim 3
 wherein an antiviral is administered during the course of the viral infection.
8. The method of
claim 4
 wherein an antiviral is administered during the course of the viral infection.
9. The method of
claim 1
 wherein the inhibitor is administered orally as a controlled-release tablet.
10. The method of
claim 1
 wherein the inhibitor is administered intranasally or by aerosol to the respiratory tract.
US09/779,401 2000-02-09 2001-02-08 Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection Expired - Fee Related US6436971B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/779,401 US6436971B2 (en) 2000-02-09 2001-02-08 Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18138500P 2000-02-09 2000-02-09
US09/779,401 US6436971B2 (en) 2000-02-09 2001-02-08 Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection

Publications (2)

Publication Number Publication Date
US20010041739A1 true US20010041739A1 (en) 2001-11-15
US6436971B2 US6436971B2 (en) 2002-08-20

Family

ID=26877137

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/779,401 Expired - Fee Related US6436971B2 (en) 2000-02-09 2001-02-08 Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection

Country Status (1)

Country Link
US (1) US6436971B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006052A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
WO2010095041A2 (en) * 2009-02-18 2010-08-26 Excrx (Singapore) Pte.Ltd. Compositions, methods, and kits for treating influenza viral infections
WO2011127019A3 (en) * 2010-04-07 2011-12-01 Celgene Corporation Methods for treating respiratory viral infection

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570344A (en) * 2002-09-20 2010-04-30 Arrow Therapeutics Ltd Benzodiazepine derivatives and pharmaceutical compositions containing them
EP1633306A4 (en) * 2003-05-29 2007-05-16 Merck & Co Inc Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders
ATE499903T1 (en) * 2004-03-18 2011-03-15 Contipi Ltd DEVICE FOR TREATING ORGAN PROlapse IN THE FEMALE PELVIS
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20110201665A1 (en) * 2009-02-18 2011-08-18 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239477T1 (en) * 1995-08-02 2003-05-15 Darwin Discovery Ltd QUINOLONES AND THEIR THERAPEUTIC USE
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006052A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
WO2008006051A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
WO2008006051A3 (en) * 2006-07-07 2008-06-26 Steven P Govek Bicyclic heteroaryl inhibitors of pde4
WO2008006052A3 (en) * 2006-07-07 2008-11-20 Steven P Govek Bicyclic heteroaryl inhibitors of pde4
WO2010095041A2 (en) * 2009-02-18 2010-08-26 Excrx (Singapore) Pte.Ltd. Compositions, methods, and kits for treating influenza viral infections
WO2010095041A3 (en) * 2009-02-18 2011-01-06 Excrx (Singapore) Pte.Ltd. Compositions, methods, and kits for treating influenza viral infections
WO2011127019A3 (en) * 2010-04-07 2011-12-01 Celgene Corporation Methods for treating respiratory viral infection
US9408831B2 (en) 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection

Also Published As

Publication number Publication date
US6436971B2 (en) 2002-08-20

Similar Documents

Publication Publication Date Title
CN104023719B (en) Use of glutaryl histamine to treat respiratory tract diseases
Russell et al. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection.
CN115515560B (en) Treatment of coronavirus infection
US6436971B2 (en) Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
CN109789193A (en) α inhibits the method for protein for treatment tuberculosis between use
CN113244212B (en) Application of baicalein in preparing medicament for preventing and/or treating novel coronavirus infection diseases
RU2596785C2 (en) Composition containing peptide and virus neuraminidase inhibitor
CN112135625B (en) Medicine for preventing or treating COVID-19 new coronary pneumonia and application thereof
WO2021207325A1 (en) Natural extract and their components for use in mitigating acute respiratory distress syndrome
CN112386595A (en) Pharmaceutical composition for treating viral infection of respiratory system
SK1012004A3 (en) Use of azithromycin for the manufacture of a medicament for the treatment of respiratory infections in humans
WO2021231314A1 (en) Methods of treating covid-19 using tetracycline compounds
BRPI0610498A2 (en) roflumilast, pharmaceutical composition, combination product and kit for the treatment of pulmonary hypertension
AU2021244009A1 (en) Pharmaceutical composition for preventing or treating epidemic RNA viral infectious disease
CN113546089A (en) Application of 1-ethyl-3, 7-dimethyl xanthine in preparation of medicine for treating pneumonia
WO2006076014A2 (en) Interferon-alpha constructs for use in the treatment of sars
US20230303964A1 (en) Antiviral treatment comprising blis containing probiotic products
JP7399976B2 (en) Medicines, foods, and their uses to prevent or treat COVID-19 novel coronavirus pneumonia
US5645819A (en) Methods of diagnosing and treating an intestinal and lung roundworm infection
CN105943540B (en) A kind of purposes of simiarenol
JP2021505559A (en) Treatment of RSV with combination products
Bender et al. Body temperature and nesting behavior following influenza challenge in mice: Effects of age
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
Hashimoto et al. DSCG Reduces RSV‐induced illness in RSV‐infected mice
CN108743581A (en) A kind of epoxy has a smile on one's face the purposes of lactone

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BEECHAM CORPORATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEMARSH, PETER L.;DILLON, SUSAN BETH;WOODNUT, GARY;REEL/FRAME:011854/0631;SIGNING DATES FROM 20010320 TO 20010329

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20100820